Open AccessNew high-dose amoxicillin with clavulanate in therapy of acute respiratory and ENT infections in children
Author(s) -
Э. Э. Локшина,
AUTHOR_ID
Publication year - 2021
Publication title -
kliničeskij razbor v obŝej medicine
Language(s) - English
Resource type - Journals
eISSN - 2782-5671
pISSN - 2713-2552
DOI - 10.47407/kr2021.2.1.00027
Subject(s) - amoxicillin , haemophilus influenzae , medicine , respiratory tract infections , intensive care medicine , antimicrobial , drug resistance , respiratory tract , respiratory system , drug , antibiotics , immunology , microbiology and biotechnology , biology , pharmacology
A significant growth of bacterial resistance to antimicrobial agents has been reported globally over the past decades. Pneumococcus and Haemophilus influenzae are the major respiratory and ENT pathogens among children in the Russian Federation. To date, the problem of rational and effective bacterial respiratory tract infections therapy remains unsettled. The emergence of the new high-dose amoxicillin with clavulanate provides additional opportunities for respiratory disease therapy in children with risk factors for drug-resistant pathogens.